Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 535 participants.
Also called NCT01522417
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 535 participants
- Sponsor
- Medicure
- Registry
-
NCT01522417
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01522417. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2018-12 (actual). Results posted on 2021-04-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
- Acronym
- SAVI-PCI
- Condition
- Myocardial Infarction
- Condition
- Acute Coronary Syndromes
- Condition
- Unstable Angina
- Intervention (Drug)
- Short Tirofiban
- Intervention (Drug)
- Eptifibatide
- Intervention (Drug)
- Long Tirofiban
- Lead sponsor
- Medicure
- Collaborator
- SCRI Development Innovations, LLC
Record details
- Record id
cardio:ct-nct01522417- Content hash
b4cb949dec44d132db3f206b56c945eb28fbe2592365a5229f156f97efe09774